Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Luis A. Carvajal, Ulrich Steidl

Research output: Contribution to journalShort survey

2 Scopus citations


Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

Original languageEnglish (US)
Pages (from-to)6-8
Number of pages3
JournalCell Stem Cell
Issue number1
StatePublished - Jul 1 2016


ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this